31
Participants
Start Date
July 27, 2021
Primary Completion Date
November 2, 2022
Study Completion Date
November 2, 2022
GFB-887
GFB-887 is a potent, small molecule inhibitor of TRPC5.
Icahn School of Medicine at Mount Sinai, New York
The Ohio State University Wexner Medical Center, Columbus
St. Clair Nephrology, Roseville
NANI Research, LLC, Hinsdale
Clinical Research Consultants, Kansas City
Prolato Clinical Research Center, Houston
Tranquility Research, Webster
Clinical Advancement Center, PLLC, San Antonio
University of Colorado Anschutz Medical Center, Aurora
Colorado Kidney Care (Denver Nephrology), Denver
Boise Kidney and Hypertension Institute, Nampa
Utah Kidney Center, Salt Lake City
Academic Medical Research Institute (AMRI), Los Angeles
Amicis Research Center, Northridge
Kidney and Hypertension Center - Apple Valley, Victorville
Providence Medical Research Center, Spokane
Southeast Renal Research Institute, Chattanooga
Lead Sponsor
Goldfinch Bio, Inc.
INDUSTRY